24/7 Market News Snapshot 01 July, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)

July 1, 2025

DENVER, Colo., 01 July, 2025 (www.247marketnews.com) – (NASDAQ:SNGX) are discussed in this article.
Soligenix, Inc. has recently seen a significant surge in its stock performance, rising 29% in pre-market trading to reach $1.690, up from the previous close of $1.310. This momentum comes with a robust trading volume of 3.83 million shares, highlighting strong investor interest and confidence in the company’s future. The spike in share value may be attributed to positive developments within the organization, suggesting that Soligenix is emerging as a noteworthy entity in the biopharmaceutical sector.

In conjunction with this market activity, Soligenix has achieved a critical milestone by successfully transferring its synthetic hypericin active ingredient manufacturing operations to the United States. This strategic move is part of the company’s collaboration with Sterling Pharma Solutions and aims to enhance the production capabilities for its novel topical treatments, HyBryte™ and SGX302, which are in development for cutaneous T-cell lymphoma (CTCL) and psoriasis.

The transition to U.S.-based manufacturing will ensure that Soligenix has access to a scalable, commercially viable production process that complies with current good manufacturing practices (cGMP). This advancement is expected to facilitate ongoing clinical trials, including the anticipated second Phase 3 study, FLASH2, which is set to commence prior to the end of 2024.

Dr. Christopher J. Schaber, President and CEO, emphasized the excitement surrounding this transition, noting the potential for larger quantities of cGMP synthetic hypericin to improve efficiency and reduce costs in production. This development aligns with Soligenix’s commitment to bringing HyBryte™ to market as a groundbreaking photodynamic therapy, further solidifying the company’s place at the forefront of treatments for rare diseases while advancing the prospects for innovative healthcare solutions.

Related news for (SNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.